Atossa Therapeutics, Inc.
NCM: ATOSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Atossa Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ATOS Z-Score →About Atossa Therapeutics, Inc.
Healthcare
Biotechnology
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
📊 Fundamental Analysis
Atossa Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -62.7%, which indicates that capital utilization is currently under pressure.
At a current price of $4.94, ATOS currently trades near the bottom of its 52-week range (8%), indicating potential value or weakness (Range: $3.76 - $19.35).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$42.54M
Trailing P/E
--
Forward P/E
-1.45
Beta (5Y)
1.34
52W High
$19.35
52W Low
$3.76
Avg Volume
140K
Day High
Day Low